94 related articles for article (PubMed ID: 7737256)
1. A phase III trial (RTOG 8610) comparing external-beam irradiation plus short-term maximal androgen blockade with radiation therapy alone for locally advanced prostate cancer. The Radiation Therapy Oncology Group.
Eur Urol; 1994; 26 Suppl 1():3. PubMed ID: 7737256
[No Abstract] [Full Text] [Related]
2. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Pilepich MV; Winter K; John MJ; Mesic JB; Sause W; Rubin P; Lawton C; Machtay M; Grignon D
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1243-52. PubMed ID: 11483335
[TBL] [Abstract][Full Text] [Related]
3. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
Lamb DS; Denham JW; Mameghan H; Joseph D; Turner S; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Kovacev O; Robertson R; Francis L; Christie D; Spry NA; Tai KH; Wynne C; Duchesne G
Radiother Oncol; 2003 Sep; 68(3):255-67. PubMed ID: 13129633
[TBL] [Abstract][Full Text] [Related]
4. Phase III trial of androgen suppression before and during radiation therapy for locally advanced prostatic cancer: abstract report of RTOG 8610. Radiation Therapy Oncology Group.
Prostate Suppl; 1994; 5():2-3. PubMed ID: 8172711
[No Abstract] [Full Text] [Related]
5. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.
Shipley WU; Lu JD; Pilepich MV; Heydon K; Roach M; Wolkov HB; Sause WT; Rubin P; Lawton CA; Machtay M
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1302-10. PubMed ID: 12459350
[TBL] [Abstract][Full Text] [Related]
6. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.
Pilepich MV; Krall JM; al-Sarraf M; John MJ; Doggett RL; Sause WT; Lawton CA; Abrams RA; Rotman M; Rubin P
Urology; 1995 Apr; 45(4):616-23. PubMed ID: 7716842
[TBL] [Abstract][Full Text] [Related]
8. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group.
Corn BW; Winter K; Pilepich MV
Urology; 1999 Sep; 54(3):495-502. PubMed ID: 10475361
[TBL] [Abstract][Full Text] [Related]
9. A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment.
Debruyne FM; Witjes WP; Schulman CC; van Cangh PJ; Oosterhof GO
Eur Urol; 1994; 26 Suppl 1():4. PubMed ID: 7737257
[No Abstract] [Full Text] [Related]
10. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
[TBL] [Abstract][Full Text] [Related]
11. Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy.
Pilepich MV; John MJ; Krall JM; McGowan D; Hwang YS; Perez CA
Am J Clin Oncol; 1990 Dec; 13(6):461-4. PubMed ID: 2146872
[TBL] [Abstract][Full Text] [Related]
12. [Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials].
Noël G; Mazeron JJ
Cancer Radiother; 2001 Apr; 5(2):205. PubMed ID: 11355590
[No Abstract] [Full Text] [Related]
13. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer.
Bolla M
Eur Urol; 1999; 35 Suppl 1():23-5; discussion 26. PubMed ID: 10081699
[TBL] [Abstract][Full Text] [Related]
14. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy.
Horwitz EM; Winter K; Hanks GE; Lawton CA; Russell AH; Machtay M
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):947-56. PubMed ID: 11240235
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
Pilepich MV; Caplan R; Byhardt RW; Lawton CA; Gallagher MJ; Mesic JB; Hanks GE; Coughlin CT; Porter A; Shipley WU; Grignon D
J Clin Oncol; 1997 Mar; 15(3):1013-21. PubMed ID: 9060541
[TBL] [Abstract][Full Text] [Related]
16. A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01).
Steigler A; Mameghan H; Lamb D; Joseph D; Matthews J; Franklin I; Turner S; Spry N; Poulsen M; North J; Kovacev O; Denham J
Australas Radiol; 2000 Feb; 44(1):65-71. PubMed ID: 10761262
[TBL] [Abstract][Full Text] [Related]
17. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.
Bolla M; Collette L; Blank L; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Mattelaer J; Lopez Torecilla J; Pfeffer JR; Lino Cutajar C; Zurlo A; Pierart M
Lancet; 2002 Jul; 360(9327):103-6. PubMed ID: 12126818
[TBL] [Abstract][Full Text] [Related]
18. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
Lawton CA; Winter K; Grignon D; Pilepich MV
J Clin Oncol; 2005 Feb; 23(4):800-7. PubMed ID: 15681524
[TBL] [Abstract][Full Text] [Related]
19. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
Scalliet P
Acta Urol Belg; 1996 May; 64(2):63-4. PubMed ID: 8701815
[No Abstract] [Full Text] [Related]
20. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
Fair WR; Cookson MS; Stroumbakis N; Cohen D; Aprikian AG; Wang Y; Russo P; Soloway SM; Sogani P; Sheinfeld J; Herr H; Dalgabni G; Begg CB; Heston WD; Reuter VE
Urology; 1997 Mar; 49(3A Suppl):46-55. PubMed ID: 9123736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
